[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100523075":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":48,"centralContacts":53,"locations":54,"responsibleParty":75,"collaborators":77,"id":81,"slug":82,"hasResults":83,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":53,"eligibilityCriteria":87,"healthyVolunteers":83,"sex":88,"minAge":89,"maxAge":53,"enrollmentInfo":90,"targetDuration":53,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":53,"overallStatus":56,"whyStopped":53,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Jonsson Comprehensive Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Screening (MRI)","EXPERIMENTAL","Patients undergo one MRI scan over approximately 1 hour prior to surgery.",[13,14,15],"Procedure: Biospecimen Collection","Procedure: Magnetic Resonance Imaging","Other: Medical Chart Review",[17,26,42],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"PROCEDURE","Biospecimen Collection","patients will receive 1-3 image-guided biopsies within tumor tissue already designated for resection or removal.",[9],[23,24,25],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":18,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Magnetic Resonance Imaging","Undergo MRI scan",[9],[31,32,33,34,35,36,37,38,39,40,41],"Magnetic Resonance","Magnetic resonance imaging (procedure)","Magnetic Resonance Imaging Scan","Medical Imaging, Magnetic Resonance \u002F Nuclear Magnetic Resonance","MR","MR Imaging","MRI","MRI Scan","NMR Imaging","NMRI","Nuclear Magnetic Resonance Imaging",{"type":6,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Medical Chart Review","Review Medical Chart",[9],[47],"Chart Review",[49],{"name":50,"affiliation":51,"role":52},"Benjamin M Ellingson","UCLA \u002F Jonsson Comprehensive Cancer Center","PRINCIPAL_INVESTIGATOR",null,[55],{"facility":51,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"RECRUITING","Los Angeles","California","90095","United States","US",{"type":63,"coordinates":64},"Point",[65,66],-118.24368,34.05223,{"lat":66,"lon":65},[69,74],{"name":70,"role":71,"phone":72,"phoneExt":53,"email":73},"Benjamin M. Ellingson","CONTACT","310-481-7572","bellingson@mednet.ucla.edu",{"name":70,"role":52,"phone":53,"phoneExt":53,"email":53},{"type":76,"investigatorFullName":53,"investigatorTitle":53,"investigatorAffiliation":53,"oldNameTitle":53,"oldOrganization":53},"SPONSOR",[78],{"name":79,"class":80},"National Cancer Institute (NCI)","NIH","100523075","magnetic-resonance-imaging-for-improving-knowledge-of-brain-tumor-biology-in-patients-with-resectable-glioblastoma-100523075",false,"NCT06090903","Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma","Exploration Into the Association Between Decorin (DCN) Expression and MR Phenotypes in GBM","Inclusion Criteria:\n\n* Patients \\> 18 years of age\n* Patients with newly diagnosed, suspected or recurrent glioblastoma (GBM) patients with enhancing tumors greater than 1.5 mL clinically indicated for surgical resection. Recurrent GBM must have occurred more than 3 months after the end of radiation therapy per Response Assessment in Neuro-Oncology Criteria (RANO) guidelines\n\nExclusion Criteria:\n\n* Counterindication to magnetic resonance imaging (MRI) (Patient has a pacemaker or metal in the body)\n* Patients \\\u003C 18 years of age","ALL","18 Years",{"count":91,"type":92},50,"ESTIMATED","INTERVENTIONAL",[95],"NA","This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States. Glioblastoma is a type of malignant glioma with very poor patient prognosis. There are currently only about 3 drugs approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma, one of them being administration of bevacizumab, which is very expensive. It is the most widely used treatment for glioblastoma with dramatic results. However, previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment (recurrent). The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers.",[98,99,100],"Glioblastoma","Recurrent Glioblastoma","Resectable Glioblastoma","2025-11-06",{"date":103,"type":104},"2025-11-10","ACTUAL",{"date":106,"type":104},"2022-04-14",{"date":108,"type":92},"2028-04-18",{"name":5,"class":6},1]